Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taiwan Liposome Company (TLC) has entered into a collaboration agreement with Ildong Pharmaceutical, for the marketing, distribution and sale of ProFlow, the super generic drug developed by TLC.
Subscribe to our email newsletter
TLC claims that ProFlow is an improved Prostaglandin E1 emulsion with extended shelf stability of more than two years, developed by TLC with its proprietary formulation, patented worldwide.
ProFlow is used for treating Peripheral Arterial Disease (PAD), diabetic neuropathy and ulcers.
TLC president George Yeh said that they are very much looking forward to having ProFlow distributed by such an experienced partner in Korea.
"Now we have extremely strong partners in Japan and Korea for the distribution of ProFlow, we’re most confident in the future outlook of the product and its positive reflection on TLC," Yeh said.